August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeys
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…
Webinar – How to Treat Locoregional Reccurent Disease of Nasopharyngeal Cancer
ByInnokeys
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
Update on Laryngeal Cancer
ByInnokeys
Speakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
ByInnokeys
New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeys
Speakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…